The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SU2C phase Ib study of the PI3Kα inhibitor BYL719 with letrozole in ER+/HER2– metastatic breast cancer (MBC).
Ingrid A. Mayer
Research Funding - Novartis
Vandana Gupta Abramson
No relevant relationships to disclose
Justin M. Balko
No relevant relationships to disclose
Melinda Sanders
No relevant relationships to disclose
Dejan Juric
Research Funding - Novartis
Yisheng Li
No relevant relationships to disclose
Lewis Cantley
No relevant relationships to disclose
Eric P. Winer
Consultant or Advisory Role - Novartis
Carlos L. Arteaga
Consultant or Advisory Role - Novartis